Omega 3 MarketSize, Share & Industry Analysis, 2026-2034By TypeBy SourceBy Dietary SupplementsBy ApplicationBy Form

Omega-3 refers to a family of polyunsaturated fatty acids, principally EPA, DHA and ALA, extracted from marine sources such as fish, krill and algae or from plant sources such as flaxseed, chia and soy, and sold as a standalone ingredient or a finished consumer product. Manufacturers of dietary supplements, functional foods, infant formula, pharmaceuticals and animal feed buy it as a refined oil, powder or encapsulated dose to fortify their own products with cardiovascular, cognitive or developmental health claims. Buyers range from ingredient formulators sourcing bulk concentrate to retail consumers purchasing finished softgels, liquids or gummies directly.

The global omega 3 market stood at USD 7.55 billion in 2025. A forecast-period rate of 7.2% takes it to USD 14.12 billion by 2034, and the study reports every year in between, passing USD 5.6 billion in 2020, USD 7.15 billion in 2024, USD 8.1 billion in 2026 and USD 10.69 billion in 2030.

50.6% of 2025 revenue sits in Docosahexaenoic acid (DHA), worth USD 3.82 billion and rising to USD 6.78 billion at 48.02% by 2034, the largest type line in both years. Growth is fastest in Eicosapentaenoic acid (EPA) at 8.42% and slowest in Alpha-linolenic acid (ALA) at 5.88%. Share moves toward Eicosapentaenoic acid (EPA) and away from Docosahexaenoic acid (DHA) and Alpha-linolenic acid (ALA), though no line shrinks in revenue terms.

The source split puts Fish Oil first, at USD 3.02 billion and 40% of revenue in 2025, rising to USD 4.94 billion and 35.01% in 2034. Algal Oil grows faster at 10.99% against 5.62%, moving from 10.99% of revenue to 15.02% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

North America is the largest region at 34% of 2025 revenue, worth USD 2.57 billion and reaching USD 4.38 billion by 2034. Europe follows at 27%, moving from USD 2.04 billion to USD 3.53 billion, and Middle East and Africa is the smallest at 6%. Because Asia Pacific take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

The 2025 total is triangulated from published sources and category proxies, with no independently sourced count behind it. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, three type lines and five segmentation axes across a fifteen-year window.

• The global omega 3 market moves from USD 5.6 billion in 2020 to USD 7.55 billion in 2025 and USD 14.12 billion by 2034, the forecast period compounding at 7.2% a year.
• Docosahexaenoic acid (DHA) is the largest type line at USD 3.82 billion in 2025, a 50.6% share, reaching USD 6.78 billion and 48.02% of revenue by 2034.
• Fastest growth on the type axis belongs to Eicosapentaenoic acid (EPA): 8.42% a year, USD 2.73 billion to USD 5.65 billion, and a share moving from 36.16% to 40.01%.
• The bull case puts 2034 revenue at USD 16.01 billion and the bear case at USD 12.34 billion, either side of the USD 14.12 billion base case, each with its own stated assumption in the full report.
• 34% of 2025 revenue is generated in North America, worth USD 2.57 billion and rising to USD 4.38 billion by 2034; Middle East and Africa is smallest at 6%.
• Within North America, the United States is the worked country example, at USD 2.06 billion in 2025; 80.2% of regional revenue in the base year, and USD 3.46 billion by 2034.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

The global omega 3 market is shaped over 2026-2034 by three measurable movements: a change in the type mix, a shift in where revenue sits geographically, and the 7.2% rate carrying the total.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Eicosapentaenoic acid (EPA) grows faster than Alpha-linolenic acid (ALA). Eicosapentaenoic acid (EPA) grows at 8.42% across 2026-2034 against 5.88% for Alpha-linolenic acid (ALA), the widest spread on the type axis. Shares follow: 36.16% to 40.01% for Eicosapentaenoic acid (EPA), 13.25% to 11.97% for Alpha-linolenic acid (ALA). The revenue figures behind that are USD 2.73 billion to USD 5.65 billion and USD 1 billion to USD 1.69 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Regional weight shifts toward Asia Pacific. Asia Pacific moves from 26% of revenue in 2025 to 32% in 2034, worth USD 1.96 billion rising to USD 4.52 billion. Share moves off the others in turn: North America at 34% moving to 31%, Europe at 27% moving to 25%, Latin America at 7% moving to 7%, Middle East and Africa at 6% moving to 5%, each still growing in revenue terms. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

Growth compounds at 7.2% without a step change. Year by year the total runs USD 5.6 billion in 2020, USD 7.15 billion in 2024, USD 7.55 billion in 2025, USD 8.1 billion in 2026, USD 10.69 billion in 2030 and USD 14.12 billion in 2034. There is no discontinuity to time, and 7.2% forecast growth against 6.15% historical means the trend continues and does not turn. That moves the planning question away from timing a turn and onto the type and regional mixes, where the actual movement is.

Eicosapentaenoic acid (EPA) carries the market's growth rate

Growth in the global omega 3 market comes from three measurable sources over 2026-2034: the market's own compounding at 7.2%, the share gained by faster-growing type lines, and expansion in the regions taking a larger part of global revenue.

The bear case and what drives it

Where the forecast could be beaten

Concentration on the type axis

34% of the global omega 3 market sits in North America in 2025, worth USD 2.57 billion with USD 4.38 billion projected for 2034. It is a leading region on this axis, first by revenue throughout the period.

By 2034 the share stands at 31%, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Segment composition follows the global pattern: Docosahexaenoic acid (DHA) largest at 50.6% of 2025 revenue, Eicosapentaenoic acid (EPA) fastest at 8.42%. North America is reported axis by axis and country by country in the full study.

The largest single market in North America is the United States, at USD 2.06 billion in 2025 and USD 3.46 billion in 2034. 80.2% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Against regional totals of USD 2.57 billion in 2025 and USD 4.38 billion in 2034, it is the country the full report breaks out in detail.

Demand in the United States follows the type mix reported at global level: Docosahexaenoic acid (DHA) is the largest line at 50.6% of 2025 revenue, moving to 48.02% by 2034, while Eicosapentaenoic acid (EPA) grows fastest at 8.42% and takes its share from 36.16% to 40.01%. Since 80.2% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The United States carries its own type breakdown in the full report.

Omega-3 products intended as dietary supplements fall under the Food and Drug Administration's framework for supplements rather than drugs, which means a manufacturer is responsible for ensuring safety and truthful labelling before marketing, without needing premarket approval for the finished product itself. Ingredient sourcing still matters: a novel omega-3 source or extraction method may trigger a New Dietary Ingredient notification. Labelling must follow the Supplement Facts panel format, disclose allergens such as fish or shellfish where relevant, and avoid disease-treatment claims, which would reclassify the product as a drug. Where omega-3 is added to conventional foods instead, it is treated as a food ingredient and must meet Generally Recognized As Safe standards. Manufacturing facilities are expected to operate under current Good Manufacturing Practice rules for dietary supplements, covering identity testing, purity, and contaminant control.

Competition in the United States runs between the suppliers this study tracks: Aker Biomarine Antarctic AS, Orkla Health, BASF SE, Omega Protein Corp., GC Reiber Oils, Lonza, Croda International Plc, EPAX, BioProcess Algae, LLC and Koninklijke DSM N.V.. Two different problems sit on the same axis: holding Docosahexaenoic acid (DHA) at 50.6% of 2025 revenue, and taking Eicosapentaenoic acid (EPA) while it grows at 8.42%. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

6.8% of global revenue is generated in Canada; USD 0.51 billion in 2025, reaching USD 0.92 billion in 2034, and 19.8% of North America.

In Europe, 27% of global revenue puts 2025 at USD 2.04 billion rising to USD 3.53 billion in 2034. Among the five regions it ranks second by revenue in both years.

25% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Docosahexaenoic acid (DHA) largest at 50.6% of 2025 revenue, Eicosapentaenoic acid (EPA) fastest at 8.42%. The full report breaks Europe out along every axis and by country.

Germany is the largest market within Europe, generating USD 0.65 billion in 2025 and projected to reach USD 1.09 billion by 2034. 31.9% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 2.04 billion in 2025 and USD 3.53 billion in 2034, it is the country the full report breaks out in detail.

Germany buys along the same lines as the market globally; Docosahexaenoic acid (DHA) first at 50.6% of 2025 revenue and 48.02% in 2034, Eicosapentaenoic acid (EPA) fastest at 8.42% on a share moving from 36.16% to 40.01%. With 31.9% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for Germany is reported separately in the full report.

As an EU member state, Germany applies the Novel Food Regulation and general food law to omega-3 products, meaning any ingredient or extraction process not established as commonly consumed before the relevant cutoff period needs authorisation before sale. Fish oil and algal oil sources with a recognised history of use can generally be marketed as food supplements under the EU Food Supplements Directive, which sets purity and compositional requirements alongside national implementing rules enforced by German food safety authorities. Labelling must comply with the Health Claims Regulation, so any statement about heart or cognitive benefit must be a claim already authorised for that nutrient rather than invented by the seller. Packaging must also meet the Food Information Regulation's requirements for ingredient listing, allergen disclosure, and nutrition declaration, and products are subject to routine market surveillance rather than premarket licensing.

The suppliers tracked in this study (Aker Biomarine Antarctic AS, Orkla Health, BASF SE, Omega Protein Corp., GC Reiber Oils, Lonza, Croda International Plc, EPAX, BioProcess Algae, LLC and Koninklijke DSM N.V.) compete in Germany across the type lines above. Docosahexaenoic acid (DHA), at 50.6% of 2025 revenue, is where the volume sits, and Eicosapentaenoic acid (EPA), growing at 8.42%, is where position changes hands over the forecast period. Weighting toward Europe means competing for 27% of 2025 global revenue, a base of USD 2.04 billion moving to USD 3.53 billion across the forecast period.

Within Europe, France accounts for 22.1% of regional revenue and 6% of the global total, worth USD 0.45 billion in 2025 and USD 0.74 billion by 2034.

5.4% of global revenue is generated in the United Kingdom; USD 0.41 billion in 2025, reaching USD 0.67 billion in 2034, and 20.1% of Europe.

Asia Pacific holds 26% of the global omega 3 market in 2025, worth USD 1.96 billion rising to USD 4.52 billion in 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

Its share rises to 32% over the forecast period, so the region grows faster than the market's 7.2% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Within the region the type split tracks the global one; 50.6% of 2025 revenue in Docosahexaenoic acid (DHA), fastest growth of 8.42% in Eicosapentaenoic acid (EPA). Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

34.2% of Asia Pacific's base-year revenue comes from China; USD 0.67 billion, rising to USD 1.49 billion by 2034. Its 34.2% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Against regional totals of USD 1.96 billion in 2025 and USD 4.52 billion in 2034, it is the country the full report breaks out in detail.

China buys along the same lines as the market globally; Docosahexaenoic acid (DHA) first at 50.6% of 2025 revenue and 48.02% in 2034, Eicosapentaenoic acid (EPA) fastest at 8.42% on a share moving from 36.16% to 40.01%. Its 34.2% weight in Asia Pacific means those movements carry straight into the regional totals. Per-type revenue for China appears on its own in the full report.

Omega-3 products sold as health foods in China fall under the National Medical Products Administration's health food regime, which historically required formal registration for new formulations, though many standard vitamin and mineral or well-established ingredient categories can instead follow a simplified filing pathway. A supplier must demonstrate that raw material sourcing and production meet national food safety standards, and imported products face additional customs and labelling review before they can be sold domestically. Where omega-3 is marketed as an ordinary food ingredient instead of a health food, it falls under general food safety law administered by the State Administration for Market Regulation, with different labelling obligations. Health food packaging must carry the distinctive blue-hat mark once approved, and claims are restricted to those matched against the approved registration or filing, with no allowance for open-ended therapeutic wording.

The suppliers tracked in this study (Aker Biomarine Antarctic AS, Orkla Health, BASF SE, Omega Protein Corp., GC Reiber Oils, Lonza, Croda International Plc, EPAX, BioProcess Algae, LLC and Koninklijke DSM N.V.) compete in China across the type lines above. Two different problems sit on the same axis: holding Docosahexaenoic acid (DHA) at 50.6% of 2025 revenue, and taking Eicosapentaenoic acid (EPA) while it grows at 8.42%. The commercial size of that position is USD 1.96 billion in 2025 and USD 4.52 billion by 2034, 26% of the global total in the base year.

Within Asia Pacific, Japan accounts for 24% of regional revenue and 6.2% of the global total, worth USD 0.47 billion in 2025 and USD 0.9 billion by 2034.

Within Asia Pacific, India accounts for 15.8% of regional revenue and 4.1% of the global total, worth USD 0.31 billion in 2025 and USD 0.9 billion by 2034.

7% of the global omega 3 market sits in Latin America in 2025, worth USD 0.53 billion and reaches USD 0.99 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

Share settles at 7% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the type split tracks the global one; 50.6% of 2025 revenue in Docosahexaenoic acid (DHA), fastest growth of 8.42% in Eicosapentaenoic acid (EPA). Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

54.7% of Latin America's base-year revenue comes from Brazil; USD 0.29 billion, rising to USD 0.53 billion by 2034. 54.7% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 0.53 billion to USD 0.99 billion over the same period, and this is the market carrying the country-level detail in the full report.

Brazil buys along the same lines as the market globally; Docosahexaenoic acid (DHA) first at 50.6% of 2025 revenue and 48.02% in 2034, Eicosapentaenoic acid (EPA) fastest at 8.42% on a share moving from 36.16% to 40.01%. Its 54.7% weight in Latin America means those movements carry straight into the regional totals. The full report reports Brazil by type separately.

Brazil's health regulatory agency, ANVISA, governs omega-3 products under its framework for food supplements, which sets identity, purity, and composition requirements for fish oil, algal oil, and other marine-derived sources. A supplier must ensure the product is notified or registered according to ANVISA's supplement category rules before distribution, and manufacturing sites are expected to follow good manufacturing practice standards consistent with ANVISA's food safety inspection regime. Labelling must state the source of the omega-3 fatty acids, include allergen warnings where fish or shellfish derivatives are present, and avoid disease-related claims unless specifically permitted under ANVISA's health claims guidance. Imported products additionally require compliance with Brazilian customs and sanitary import procedures, and any claim referencing cardiovascular or developmental benefit must align with the substantiation categories ANVISA already recognises for that nutrient class.

In Brazil the field is Aker Biomarine Antarctic AS, Orkla Health, BASF SE, Omega Protein Corp., GC Reiber Oils, Lonza, Croda International Plc, EPAX, BioProcess Algae, LLC and Koninklijke DSM N.V.. Volume sits in Docosahexaenoic acid (DHA) at 50.6% of 2025 revenue; movement sits in Eicosapentaenoic acid (EPA) at 8.42% growth. A supplier weighted toward Latin America is competing over a base of USD 0.53 billion in 2025 reaching USD 0.99 billion by 2034, 7% of global revenue at the start of that period.

2.1% of global revenue is generated in Mexico; USD 0.16 billion in 2025, reaching USD 0.29 billion in 2034, and 30.2% of Latin America.

USD 0.45 billion of 2025 revenue is generated in Middle East and Africa, 6% of the global omega 3 market with USD 0.71 billion projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

Its share moves to 5% by 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the type split tracks the global one; 50.6% of 2025 revenue in Docosahexaenoic acid (DHA), fastest growth of 8.42% in Eicosapentaenoic acid (EPA). Per-axis and per-country detail for Middle East and Africa sits in the full report.

USD 0.16 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.24 billion by 2034. It accounts for 35.6% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 0.45 billion in 2025 and USD 0.71 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Docosahexaenoic acid (DHA) at 50.6% of 2025 revenue, easing to 48.02% by 2034, and the fastest is Eicosapentaenoic acid (EPA) at 8.42%, from 36.16% to 40.01%. Since 35.6% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Saudi Arabia carries its own type breakdown in the full report.

The Saudi Food and Drug Authority regulates omega-3 products under its food and nutritional supplement framework, requiring registration of the product and its facility before it can be marketed within the Kingdom. Suppliers must demonstrate that the formulation, sourcing, and manufacturing process meet SFDA's safety and quality requirements, and imported products undergo border inspection and documentation checks confirming registration status. Labelling must be presented in Arabic alongside any other language, disclose the fish or marine source clearly for allergen purposes, and carry only claims that SFDA has approved for that nutrient category. As a member of the Gulf Cooperation Council, Saudi Arabia also aligns elements of its supplement standards with GCC technical regulations, giving suppliers a broader regional conformity pathway once national registration is secured, though SFDA approval remains the binding requirement for sale within the country itself.

Aker Biomarine Antarctic AS, Orkla Health, BASF SE, Omega Protein Corp., GC Reiber Oils, Lonza, Croda International Plc, EPAX, BioProcess Algae, LLC and Koninklijke DSM N.V. are the suppliers covered in Saudi Arabia. Two different problems sit on the same axis: holding Docosahexaenoic acid (DHA) at 50.6% of 2025 revenue, and taking Eicosapentaenoic acid (EPA) while it grows at 8.42%. That makes Middle East and Africa a 6% share of 2025 global revenue, USD 0.45 billion rising to USD 0.71 billion, for any supplier deciding where to concentrate.

1.5% of global revenue is generated in South Africa; USD 0.11 billion in 2025, reaching USD 0.17 billion in 2034, and 24.4% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, source, dietary supplements, application, form, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.